From Jan. 1985 to Feb. 1986, 180 patients with esophageal, carcinoma were entered into this study. All patients were inoperable or who refused operation. Because parts of the cases data were lost, the number of analysed cases was 137. All patients were followed for at least 5-year. Patients were randomly divided into four groups: A, control group (radiation alone with the dose of 55～65 Gy in 5～7 weeks) 32 patients. B, radiation plus ping yangmycin (10mg im, twice a week), 37 patients. C, radiation plus cisplatin (20mg, iv. twice a week) 40 patients.D, radiation plus both 28 patients. The 3-year survival rates were 15.6%, 21.6%, 42.5% and 39.3%, respectively. There were significantly differences between C and A or D and B groups, respectively (P

Peritoneal metastasis is considered as the end stage of gastric cancer, which is a fatal malignancy without the chance of surgery. No standard regimens are recommended. Routine treatments can not improve the survival of these patients, while multidisciplinary treatments may probably be promising. Aggressive treatments such as cytoreductive surgery, intra-peritoneal chemotherapy and bidirectional chemotherapy are applied to clinical management in recent years. Furthermore, molecular targeted therapy and immune therapy are developed and making individualized treatment possible. Individualized treatment according to clinical characteristics and expression of biomarkers will be the future of peritoneal metastasis of gastric cancer.
Combined Modality Therapy ; Humans ; Peritoneal Neoplasms ; Precision Medicine ; Stomach Neoplasms

BACKGROUNDTo investigate gene diagnosis of micrometastasis in lymph nodes in patients with non-small cell lung cancer (NSCLC) and the feasibility of mucin 1 (MUC1) mRNA and cytokeratin 19 (CK19) mRNA as molecular marker to detect micrometastasis of lung cancer.

METHODSExpression of MUC1 mRNA and CK19 mRNA was detected in 119 lymph nodes taken from 31 patients with NSCLC, 35 lymph nodes from 10 patients with pulmonary benign diseases as controls by nested reverse transcriptase-polymerase chain reaction (RT-PCR).

RESULTSIn the 119 lymph nodes from lung cancer patients, CK19 mRNA expression was detected in 66 lymph nodes (55.5%) and MUC1 mRNA expression was detected in 65 lymph nodes (54.5%) by RT-PCR. Neither CK19 mRNA nor MUC1 mRNA expression was observed in all the 35 lymph nodes in the benign pulmonary lesion group.

CONCLUSIONSThe results suggest that the detection of both MUC1 and CK19 mRNA might be helpful to diagnose NSCLC micrometastasis in lymph nodes. The establishment of this method may lead to an earlier diagnosis of metastasis for lung cancer.